View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. AqVida
19 April 2009

AqVida Licenses in Technology for Generic Oxaliplatin

Despite fierce competition on generic Oxaliplatin, AqVida is convinced it can generate major sales of the product due to the low level of production costs and transfer prices.

The product will be available for out-licensing in August. AqVida has confirmed talks with several interested companies throughout Europe have been initiated.

This is the third such development by the company, which was founded in 2004 and is mainly known for its bio-similar Filgrastim, which is registered under the trade name Leucita in Russia and under registration in several other countries in Eastern Europe and Latin America.

AqVida is involved in the the development, registration and supply of generic oncology products and biosimilars, and also supplies active pharmaceutical ingredients (API) with all...
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology